Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer

Radiotherapy and Oncology

Volumn 47, Issue 2, 1998, Pages 175-183

  Grabenbauer, Gerhard G ^a   Steininger, Helmuth ^a   Meyer, Martin ^a   Fietkau, Rainer ^a   Brunner, Thomas ^a   Heinkelmann, Pia ^a   Hornung, Joachim ^a   Iro, Heiner ^a   Spitzer, Wolfgang ^a   Distel, L ^a   Kirchner, Thomas ^a   Sauer, Rolf ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Head and neck cancer; Nodal CT density; Prognostic factors; Proliferation; Radiotherapy; Tumor volume

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7144251867     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00016-4     Document Type: Article

References (49)

1. Ahomadegbe, J.C., Barrois, M., Bihan, M.L., et al. High incidence of p53 alterations (mutations, deletions, overexpression) in head and neck primary tumors and metastases, absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10: 1217-1227, 1995.
2. Anwar, K., Nakakuki, K., Imai, H., Naiki, H. and Inuzuka, M. Overexpression of p53 protein in human laryngeal carcinoma. Int. J. Cancer 53: 952-956, 1993.
3. Bataini, J.P., Aselaine, B., Jaulerry, Ch., et al. A multivariate primary tumor control analysis in 465 patients treated by radical radiotherapy for cancer of the tonsilar region: clinical and treatment parameters as prognostic factors. Radiother. Oncol. 14: 265-277, 1989.
4. Beck-Bornholdt, H.P., Dubben, H.H., Liertz-Petersen, C. and Willers, H. Hyperfractionation: where do we stand? Radiother. Oncol. 43: 1-21, 1997.
5. Bolton, W.E., Mikulka, W.R. and Healy, G.G. Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry 13: 117-126, 1992.
6. Bourhis, J., Dendale, R., Hill, C., et al. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int. J. Radiat. Oncol. Biol. Phys. 35: 471-476, 1996.
7. Bravo, R., Frank, R., Blundell, P.A. and Macdonald-Bravo, P.A. Cyclin/PCNA is the auxiliary protein of DNA polymerase delta. Nature 326: 515-516, 1987.
8. Clarke, A.R., Purdie, C.A., Harrison, D.J., et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 326: 849, 1993.
9. Collins, C.D., Constant, O., Fryatt, I., Blake, P.R. and Parsons, C.A. Relationship of computed tomography tumor volume to patient survival in carcinoma of the cervix treated by radical radiotherapy. Br. J. Radiol. 67: 252-256, 1994.
10. Cox, D.R. Regression models and life tables. J. R. Stat. Soc. B34: 187-202, 1972.
11. Fietkau, R., Iro, H., Altendorf, A. and Sauer, R. Prognostic value of cellular DNA content and s-phase fraction in head and neck squamous cell carcinomas in relation to different treatment modalities. Radiat. Oncol. Invest. 1: 50-62, 1993.
12. Fietkau, R., Iro, H., Tulusan, A.H., Dressel, V. and Sauer, R. Prognostic value of s-phase fraction in head and neck squamous cell carcinomas and node negative breast carcinomas. Strahlenther. Onkol. 170: 13-24, 1994.
13. Fowler, J. and Lindstrom, M.J. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23: 457-467, 1992.
14. Frank, J.L., Bur, M.E., Garb, J.L., et al. p53 tumor suppressor gene expression in squamous cell carcinoma of the hypopharynx. Cancer 73: 181-186, 1994.
15. Fu, K.K., Hammond, E., Pajak, T.F., et al. Flow cytometric quantification of the proliferation associated nuclear antigen p105 and DNA content in advanced head and neck cancers: results of RTOG 91-08. Int. J. Radiat. Oncol. Biol. Phys. 29: 661-671, 1994.
16. Gasparini, G., Weidner, N., Maluta, S., et al. Intratumoral microvessel density and p53 protein: correlations with metastasis in head and neck squamous cell carcinoma. Int. J. Cancer 55: 739-744, 1993.
17. Gerdes, J., Schwab, U., Lemke, H. and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31: 13-20, 1983.
18. Gilbert, R.W., Birt, D., Shulman, H., et al. Correlation of tumor volume with local control in laryngeal carcinoma treated by radiotherapy. Ann. Otol. Rhinol. Laryngol. 96: 514-518, 1987.
19. Günzl, H.J., Horn, H., Schücke, R. and Donath, K. Prognostic value of PCNA and cytokeratins for radiation therapy of oral squamous cell carcinoma. Oral Oncol. Eur. J. Cancer 29B: 141-145, 1993.
20. Hake, R., Eckel, E., Von Pritzbuer, E., Volling, P. and Thiele, J. Wertigkeit monoklonaler Antikörper (PC10, MIB1, p53 und LeuM1) für die Abschätzung der Prognose von Patienten mit Plattenepithelkarzinomen des Larynx nach Laserresektion. Pathologe 16: 197-203, 1995.
21. Hermans, R., Lambin, P., van den Bogaert, W., Haustermans, K., van der Groten, A. and Baert, A.L. Non-invasive tumour perfusion measurements by dynamic CT: preliminary results. Radiother. Oncol. 44: 159-162, 1997.
22. Horiot, J.C., Le Fur, R., N'Guyen, T.N., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomised trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 25: 231-241, 1992.
23. Johnson, C.R., Khanelwal, S.R., Schmidt-Ulrich, R.K., Ravalese, J. and Wazer, D.E. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys. 32: 635-641, 1995.
24. Kaplan, E.L. and Meier, P., Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457-481, 1958.
25. Kastan, M.B., Onyekwhere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. Participation of the p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311, 1991.
26. Key, G., Becker, M.H.G., Baron, B., Duchrow, M., Schlüter, C. and Gerdes, J. New Ki-67 equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab. Invest. 68: 629-639, 1993.
27. Koch, W.M., Brennan, J.A., Zahurak, M., et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88: 1580-1585, 1996.
28. Lane, D.P. p53, guardian of the genome. Nature 141: 15-16, 1992.
29. La Vecchia, C., Boyle, B., Franceschi, B., et al. Smoking and cancer with emphasis on Europe. Eur. J. Cancer 27: 94-104, 1991.
30. Lee, N.K., Ye, Y.W., Chen, J., Li, X. and Waber, P.G. p53 and human papilloma virus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. Arch. Otolaryngol. Head Neck Surg. 119: 1125-1131, 1993.
31. Leedy, D.A., Trune, D.R., Kronz, J.D., Weidner, N. and Cohen, J.I. Tumor angiogenesis, the p53 antigen and cervical metastasis in squamous cell carcinoma of the tongue. Otolaryngol. Head Neck Surg. 111: 417-422, 1994.
32. Lewenson-Fuchs, I., Munck-Wikland, E., Berke, Z., et al. Involvement of aberrant p53 expression in human papillomavirus in carcinoma of the head, neck and esophagus. Anticancer Res. 14: 1281-1286, 1994.
33. Maciejewski, B., Withers, H.R., Taylor, J.M.G. and Hliniak, A. Dose fractionation and regeneration in radiotherapy of cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int. J. Radiat. Oncol. Biol. Phys. 16: 831-843, 1989.
34. MacCormick, D. and Hall, P.A. The complexities of proliferating cell nuclear antigen. Histopathology 21: 591-594, 1992.
35. Merlano, M., Vitale, V., Rosso, R., et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327: 1115-1121, 1992.
36. Munck, J.N., Cvitkovic, J.D., Piekarski, J.D., et al. Computed tomographic density of metastatic lymph nodes as a treatment related prognostic factor in advanced head and neck cancer. J. Natl. Cancer Inst. 83: 569-575, 1991.
37. Munck-Wikland, E., Fernber, J., Kuylenstierna, R., Lindholm, J. and Auer, G. PCNA expression and nuclear DNA content in predicting recurrence after radiotherapy of early glottic cancer. Oral Oncol. Eur. J. Cancer 29B: 75-79, 1993.
38. Nordsmark, M., Overgaard, M. and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41: 31-39, 1996.
39. Overgaard, J. Importance of tumor hypoxia in radiotherapy. A metaanalysis of controlled clinical trials. Radiother. Oncol. 24: S64, 1992.
40. Parkin, D.M., Läärä, E. and Muir, C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 41: 184-197, 1988.
41. Sanchiz, F., Milla, A., Torner, J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 19: 1347-1350, 1990.
42. Stuschke, M. and Thames, H. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 37: 259-267, 1997.
43. UICC: TNM-Classification of Malignant Tumors, 4th edn., pp. 3-20. Editors: P. Hermanek, O. Scheibe, B. Spiessl and G. Wagner. Springer, Berlin, 1987, Revision, 1992.
44. Van den Bogaert, W., van der Schueren, E., Horiot, J.C., et al. The EORTC randomised trial on three fractions per day and misonidazol in advanced head and neck cancer: prognostic factors. Radiother. Oncol. 35: 100-106, 1995.
45. Wang, H.-M., Ng, S.-H., Wang, C.-H., Liaw, M.-H. and Lai, G.-M. Correlation between computed tomographic density of lymph node metastases and response to cisplatin based chemotherapy in patients with head and neck squamous cell carcinoma in an area in which betel chewing is prevalent. Cancer 78: 1972-1979, 1996.
46. Wendt, T.G., Wustrow, T.P.U. and Schalhorn, A. Ergebnisse der simultanen Radiochemotherapie bei fortgeschrittenen Kopf-Hals-tumoren. Strahlenther. Onkol. 166: 569-579, 1990.
47. Wendt, T.G., Grabenbauer, G.G., Thiel, H.J., et al. Simultaneous radiochemotherapy versus radiotherapy alone in stage III/IV carcinoma of the head and neck. J. Clin. Oncol. 1998, in press.
48. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48, WHO, Geneva, 1979.
49. Zölzer, F., Hillebrandt, S. and Streffer, C. Radiation induced G1-block and p53 status in six human cell lines. Radiother. Oncol. 37: 20-28, 1995.